In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback